GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » Degree of Operating Leverage

DAWN (Day One Biopharmaceuticals) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Day One Biopharmaceuticals does not have enough data to calculate Degree of Operating Leverage.


Day One Biopharmaceuticals Degree of Operating Leverage Historical Data

The historical data trend for Day One Biopharmaceuticals's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Day One Biopharmaceuticals Degree of Operating Leverage Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial - - - - -

Day One Biopharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Day One Biopharmaceuticals's Degree of Operating Leverage

For the Biotechnology subindustry, Day One Biopharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Day One Biopharmaceuticals's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's Degree of Operating Leverage falls into.


;
;

Day One Biopharmaceuticals Degree of Operating Leverage Calculation

Day One Biopharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -191.57 (Mar. 2025) / -226.976 (Mar. 2024) - 1 )/( 161.922 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=-0.156/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Day One Biopharmaceuticals  (NAS:DAWN) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Day One Biopharmaceuticals Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Day One Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
Executives
York Charles N Ii officer: COO, CFO and Secretary 901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Jeremy Bender director, officer: Chief Executive Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Samuel C. Blackman officer: Chief Medical Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Ai Day 1 Llc 10 percent owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p. 10 percent owner 2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone director 395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080